What is Magellan Diagnostics?
Magellan Diagnostics is a medical device company headquartered in Billerica, Massachusetts. The company specializes in providing point-of-care systems, clinical laboratory instruments, and analytical laboratory services with a primary focus on lead testing. Magellan is committed to raising awareness about the detrimental health effects of lead exposure and offers reliable products designed for the rapid identification of individuals affected by lead. Its offerings cater to families, clinicians, policymakers, payers, and communities, aiming to mitigate the permanent physical and mental health damage associated with lead exposure.
How much funding has Magellan Diagnostics raised?
Magellan Diagnostics has raised a total of $50M across 1 funding round:
Private Equity
$50M
Private Equity (2006): $50M with participation from Ampersand Capital Partners, Tekla Capital Management, and Abingworth
Key Investors in Magellan Diagnostics
Ampersand Capital Partners
Ampersand Capital Partners is a private equity firm focused on growth-oriented investments in the healthcare sector, leveraging its expertise to build market-leading companies.
Tekla Capital Management
Tekla Capital Management, part of Aberdeen Investments, is a global asset manager providing investment solutions across various asset classes, with an emphasis on sustainable and innovative strategies in the financial sector.
Abingworth
Abingworth is a transatlantic life sciences investment firm that provides capital and expertise to companies developing novel medicines, focusing on seed, early-stage, and development-stage investments.
What's next for Magellan Diagnostics?
The recent major strategic investment suggests Magellan Diagnostics is poised for significant expansion and further innovation in its lead testing technologies. This capital infusion will likely fuel advancements in product development, market penetration, and potentially broaden the scope of its diagnostic services. The company's focus on a critical public health issue positions it for continued growth and impact, with strategic partnerships and technological enhancements expected to drive its future trajectory.
See full Magellan Diagnostics company page
